Daily non-political popular news in brief.
Latest drugs improve survival for metastatic breast cancer
07-23-2007 · EurekAlert!Newer drug therapies available since the 1990s, in particular aromatase inhibitors, improve the survival of women with metastatic breast cancer in the general population, according to a new study.
Read more »
Keywords: latest, drugs, improve, survival, metastatic, breast, cancer, drug
« Previous | Next »
Similar news on "Latest drugs improve survival for metastatic breast cancer":
- New biomarker predicts effectiveness of breast cancer drugs
12-07-2006 · EurekAlert!
University of Cincinnati researchers have identified a new way to predict when anti-estrogen drug therapies are inappropriate for patients with hormone-dependent breast cancer.Scientists say these findings could help physicians more accurately predict which tumors will respond to anti-estrogen therapy and improve long-term survival for breast cancer patients.
Similar news · Read more »
- Anthracyclines improve survival in HER2-positive breast cancer patients
12-25-2007 · EurekAlert!
Treatment with the class of chemotherapy drugs called anthracyclines improves survival in women with HER2-positive breast cancer who have previously had surgery, but it may not offer any benefit for women with HER2-negative tumors, according to a study published online Dec. 25 in the Journal of the National Cancer Institute.
Similar news · Read more »
- Bevacizumab found to improve survival for patients with advanced breast cancer
12-26-2007 · EurekAlert!
Inhibiting the growth of blood vessels that supply tumors slows the progression of metastatic breast cancer according to results of a large clinical trial of Avastin, an antiangiogenic therapy. The study, published in the Dec. 27 issue of the New England Journal of Medicine, found that Avastin in combination with chemotherapy significantly prolongs progression-free survival for women with breast cancer compared to chemotherapy alone.
Similar news · Read more »
- Group therapy fails to improve breast cancer survival
07-23-2007 · EurekAlert!
A follow up to a previous study on group therapy in breast cancer patients finds group therapy does not prolong the lives of women with metastatic breast cancer.
Similar news · Read more »
- Breast cancer survival rates improved by novel drug sequence, say researchers
02-12-2007 · EurekAlert!
Changing the way women are treated for breast cancer could improve their overall chance of survival, according to research published today in the Lancet. The new paper shows that switching to a drug called exemestane, two to three years after commencing standard therapy with the drug tamoxifen, can cut the risk of death for certain women by a further 17 percent compared with using tamoxifen alone.
Similar news · Read more »
- New cancer drug hope
10-26-2006 · EurekAlert!
Scientists helping to develop the next generation of cancer-beating drugs say they have had a major breakthrough with their latest results.
Similar news · Read more »
- Gene patenting -- steep cost for health care and patients
05-07-2007 · EurekAlert!
The drug trastuzumab (Herceptin) is used to treat HER2-positive breast cancer (a type of breast cancer that overexpresses the HER2 gene and accounts for about 25 percent of all breast cancers). Trastuzumab therapy improves the chances of survival; however, it has deleterious side effects and is expensive. Thus, it is important to accurately determine the patient's HER2 status.
Similar news · Read more »
- Study suggests newer breast cancer drug may protect heart
06-08-2007 · EurekAlert!
By uncovering how one breast cancer drug protects the heart and another does not, Duke University Medical Center researchers believe they may have opened up a new way to screen drugs for possible heart-related side effects and to develop new drugs.
Similar news · Read more »
- Report on patients' access to cancer drugs 'uses flawed methods to reached flawed conclusions'
08-29-2007 · EurekAlert!
A leading epidemiologist has attacked Swedish research that looked at inequalities in patients' access to cancer drugs across Europe and the world. In a commentary published in the September issue of the cancer journal, Annals of Oncology, Professor Michel Coleman says the Karolinska report is so badly flawed that no safe conclusions can be drawn from it about cancer survival, and he highlights the role played by a major drug company in funding the research.
Similar news · Read more »
- Skin rash actually signifies better outcomes for pancreatic and lung cancer patients
07-03-2007 · EurekAlert!
The appearance of a rash in cancer patients treated with erlotinib (Tarceva) is strongly associated with longer survival, according to researchers from the drug’s developer, OSI Pharmaceuticals, Inc. This is not the first time that rash has been associated with a survival advantage with EGFR inhibitors -- a class of drugs which includes erlotinib, cetuximab, panitumumab and others designed to block overproduction of the epidermal growth factor receptor -- but it is the most detailed analysis to date.
Similar news · Read more »
